Diabetes care - Insulin delivery in a changing world

MedGenMed Medscape General Medicine

Volumn 10, Issue 5, 2008, Pages

  Marcus, Alan ^a  

^a MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; NOVOLIN R; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; VACCINE;

ADD ON THERAPY; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES CONTROL; DIABETES MELLITUS; DIET THERAPY; DISPOSABLE EQUIPMENT; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EQUIPMENT DESIGN; GENE THERAPY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; JET INJECTOR; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW; SELF CARE; SELF MONITORING; SYRINGE; TELEMEDICINE; BLOOD;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN;

EID: 44349192121     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Riddle MC. Timely initiation of basal insulin. Am J Med. 2004; 116:3S-9S.
2. Lebovitz HE, Austin MM, Blonde L, et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006;12:6-12.
3. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
4. Allen J. Insulins. Pharmacist's Letter/Prescriber's Letter. 2006;22:1-8.
5. Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145:125-134.
6. Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. MedGenMed. 2007;9:12.
7. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from Antonio Heart Study. Arch Intern Med. 1999;159:1450-1456.
8. Hardy LR, Bell RA. An epidemiological perspective on type 2 diabetes among adult men. Diabetes Spectrum. 2004;17:208-214.
9. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population. Diabetes Care. 2006;29:1263-1268.
10. Centers for Disease Control and Prevention. Prevalence of diagnosed diabetes by age, United States, 1980-2005. 2007. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/figbyage.htm. Accessed January 3, 2008.
11. Miller JL, Silverstein JH. The management of type 2 diabetes mellitus in children and adolescents. J Ped Endocrinol Metab. 2005;18:111-123.
12. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. United States, 2005. Available at: http://www.cdc.gov/diabetes/ pubs/pdf/ndfs_2005.pdf. Accessed December 12, 2007.
13. Risso A, Mercuri F, Quagliaro L, et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 2001;281:E924-E930.
14. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-1687.
15. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006;29:1486-1490.
16. Service FJ, O'Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia. 2001;44:1215-1220.
17. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care: 2007;30:S4-S41.
18. Grant RW, Buse JB, Meigs JB; University Health System Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337-442.
19. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.
20. ACE/AACE Diabetes Road Map Task Force. Road map for the prevention and treatment of type 2 diabetes. September 2005. Available at: http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf. Accessed December 12, 2007.
21. Feld S, Hellman R, Dickey RA, et al. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management: 2002 update. Endocr Pract. 2002;8:40-82.
22. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23:B21-B29.
23. Palumbo P. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med. 2004;71:385-405.
24. Rubin RR, Peyrot M, Siminerio LM; International DAWN Advisory Panel. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29:1249-1255.
25. Wagner EH, Grothaus LC, Sandhu N, et al. Chronic care clinics for diabetes in primary care: a system-wide randomized trial. Diabetes Care. 2001;24:695-700.
26. Funnell MM. Overcoming obstacles: collaboration for change. Eur J Endocrinol. 2004;151:T19-T22.
27. Centers for Disease Control and Prevention. Age-adjusted rates of annual dilated-eye exam, daily self-monitoring of blood glucose, foot examination in the last year, and doctor visit for diabetes in the last year per 100 adults with diabetes, United States, 1994-2004. Available at: http://www.cdc.gov/diabetes/statistics/preventive/tx.htm. Accessed December 12, 2007.
28. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006;295:1688-1698.
29. Klonoff DC. Diabetes and telemedicine: s the technology sound, effective, cost-effective and practical? Diabetes Care. 2003;26:1626-1628.
30. Wojcicki JM, Ladyzynski P, Krzymien J, et al. What we can really expect from telemedicine in intensive diabetes treatment: results from 3-year study on type 1 pregnant diabetic women. Diabetes Tech Ther. 2001;3:581-589.
31. Rutten GEHM, Maaijen J, Valkenburg ACH, et al. The Utrecht Diabetes project: telemedicine support improves GP care in Type 2 diabetes. Diabet Med. 2001; 18:459-463.
32. Hernando ME, Garcia G, Gómez EJ, et al. Intelligent alarms integrated in a multi-agent architecture for diabetes management. Trans Instit Measurement Control. 2004;26:185-200.
33. Chase HP, Pearson JA, Wightman C, et al. Modern transmission of glucose values reduces the costs and need for clinic visits. Diabetes Care. 2003;26:1475-1479.
34. Shea S, Weinstock RS, Starren J, et al. A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically undeserved patients with diabetes mellitus. J Am Med Inform Ass. 2006;13:40-51.
35. Flood T. Advances in insulin delivery systems and devices: beyond the vial and syringe. Insulin. 2006;1:99-108.
36. Flood TM. Appropriate use of insulin analogs in an increasingly complex type 2 diabetes mellitus (T2DM) landscape. J Farn Pract. 2007;56:S1-S12.
37. Grajower MM, Fraser CG, Holcombe JH, et al. How long should insulin be used once a vial is started? Diabetes Care. 2003;26:2665-2669.
38. Robertson KE, Glazer NB, Campbell RK. The latest developments in insulin injection devices. Diabetes Educ. 2000;26:135-152.
39. American Diabetes Association. Continuous subcutaneous insulin infusion. Diabetes Care. 2004;27:S110.
40. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27:S89-S100.
41. Stockl K, Ory C, Vanderplas A, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin. 2007;23:133-146.
42. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28:1712-1725.
43. Medicare. Formulary finder for prescription drug plans. Available at: http://formularyfinder.medicare.gov/formularyfinder. Accessed December 12, 2007.
44. Levemir formulary coverage. Available at: http://www.levemir-us.com/hcp/ payingCoverage.asp. Accessed December 12, 2007.
45. Reimbursement information. Paying for NovoLog Mix 70/30. Available at: http://www.novologmix70-30.com/reimbursement.asp. Accessed December 12, 2007.
46. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20:486-496.
47. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/ soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27:2495-2497. (Erratum in: Diabetes Care. 2004;27:3032).
48. Martin JM, Llewelyn JA, Ristic S, et al. Acceptability and safety of a new 3.0 ml re-usable insulin pen (HumaPen) in clinical use. Diabetes Nutr Metab. 1999; 12:306-309.
49. Lawton B, Berg B. Comparative evaluation of FlexPen, a new prefilled insulin delivery system, among patients and healthcare professional. Diabetes. 2001;50:A440.
50. Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26:531-540.
51. Coscelli C, Lostia S, Lunetta M, et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract. 1995;28:173-177.
52. Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the Novopen family of insulin injection devices. Clin Drug Invest. 2006;26:367-401.
53. Korytkowski M, Bell D, Jacobsen C, et al; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836-2848.
54. Einhorn D. Advances in diabetes for the millennium: insulin treatment and glucose monitoring. MedGenMed. 2004;6:8.
55. Schade DS, Valentine V. Are insulin pumps underutilized in type 1 diabetes? No. Diabetes Care. 2006;29:1453-1455.
56. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaernia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy: an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med. 2002;19:746-751.
57. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598-2603.
58. Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract. 2006;12:251-256.
59. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. Br Med J. 2002;324:1-6.
60. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26:1079-1087.
61. Retnakaran R, Hochman J, Hans deVries J, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care. 2004;27:2590-2596.
62. Nahata L. Insulin therapy in pediatric patients with type 1 diabetes: continuous subcutaneous infusion versus multiple daily injections. Clin Pediatr (Phila). 2006;45:503-508.
63. American Diabetes Association. Insulin administration. Diabetes Care. 2004;27:S106-S109.
64. Hollander PA. Evolution of a pulmonary insulin delivery system (Exubera) for patients with diabetes. MedGenMed. 2007;9:45.
65. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28:1077-1082.
66. Johnson S. Exubera blown off by Pfizer. San Jose Mercury News. October 19, 2007.
67. Skyler JS, Jovanovic L, Klioze S, et al; Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care. 2007;30:579-585.
68. Nealon A. Pharmaceutical Business Review. Available at: http://www.novonordisk.com/include/asp/ exe_news_attachment.pdf?sAttachmentGUID=1531cc83-f75c-4368-995e- f0667112304f. Accessed January 18, 2008.
69. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetes: variations with increasing levels of HbA1c. Diabetes Care. 2003;269:881-885.
70. Woerle HJ, Pimenta WP, Meyer C, et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and haemoglobin A1c values. Arch Intern Med. 2004;164:1627-1632.
71. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822-1826.
72. American Association of Diabetes Educators. AADE position statement. Self-monitodng of blood glucose: benefits and utilization. Diabetes Educ. 2006;32:835-847.
73. Benjamin EM. Self-monitoring of blood glucose: the basics. Clin Diabetes. 2002;20:45-47.
74. Karter AJ, Ackerson IM, Darbinian A et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes register. Am J Med. 2001;111:1-9.
75. Martin S, Schneider B, Heinemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006;49:271-278.
76. Davis WA, Bruce DG, Davis ME. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia. 2007;50:510-515.
77. Mehta M, Vincze G, Lopez DA. Emerging technologies in diabetes care. US Pharmacist. 2007;11:11.
78. U.S. Food and Drug Administration. Glucose meters & diabetes management. Available at: http://www.fda.gov/diabetes/glucose.html. Accessed December 12, 2007.
79. Mastrototaro JJ, Cooper KW, Soundararajan G, et al. Clinical experience with an integrated continuous glucose sensor/insulin pump platform: a feasibility study. Adv Ther. 2006;23:725-732.
80. Gabbay RA. New developments in home glucose monitoring: minimizing pain. Can J Diabetes. 2003;27:271-276.
81. Klonoff DC. Continuous glucose monitoring. Diabetes Care. 2005;28:1231-1239.
82. Bailey TS, Zisser HC, Garg SK. Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Tech Ther. 2007;9:203-210.
83. Halvorson M, Carpenter S, Kaiserman K, et al. A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous blood glucose monitoring with the insulin pump. J Pediatr. 2007;150:103-105.
84. White JR, Davis SN, Cooppan R, et al. Clarifying the role of insulin in type 2 diabetes management. Clin Diabetes. 2003;21:14-21.
85. Bretzel RG, Arnolds S, Medding J, et al. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. 2004;27:1023-1027.
86. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006;22:2613-2619.
87. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators, The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
88. Raslova K, Bogoev M, Razc I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201.
89. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
90. Rosenstock J, Schwartz SL, Clark Jr CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631-636.
91. Dornhorst A, Luddeke HJ, Sreenan S, et al; PREDICTIVE Study Group. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007;61:523-528.
92. Kripalani S, Yao X, Haynes B. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-550.
93. Clement S, Dandona P, Still JG, et al. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism. 2004;53:54-58.
94. Guevara-Aguirre J, Guevara M, Saavedra J, et al. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther. 2004;6:1-8.
95. Xuan B, McClellan DA, Moore R, et al. Alternative delivery of insulin via eye drops. Diabetes Technol Ther. 2005;7:695-698.
96. Shaikh IM, Jadhav KR, Ganga S, et al. Advanced approaches in insulin delivery. Curr Pharm Biotechnol. 2005;6:387-395.